Detailed Information

Cited 0 time in webofscience Cited 1 time in scopus
Metadata Downloads

Influence of proton pump inhibitor therapy on intestinal inflammation assessed by fecal calprotectin in pediatric patientsopen access

Authors
Kim, Su YeongLee, Na MiYun, Sin WeonChae, Soo AhnLim, In SeokChoi, Eung SangYi, Dae Yong
Issue Date
Oct-2019
Publisher
Korean Pediatric Society
Keywords
Calprotectin; Inflammation; Proton pump inhibitors
Citation
Korean Journal of Pediatrics, v.62, no.10, pp 400 - 404
Pages
5
Journal Title
Korean Journal of Pediatrics
Volume
62
Number
10
Start Page
400
End Page
404
URI
https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/37707
DOI
10.3345/kjp.2019.00115
ISSN
1738-1061
2092-7258
Abstract
Background: An increase in the numbers of patients with gastrointestinal symptoms has recently been observed. Purpose: To investigate the effects of proton pump inhibitor (PPI) therapy on intestinal inflammation in children and adolescents as confirmed by clinical manifestations and objectively assessed by fecal calprotectin (FC) level measurement. Methods: Consecutive children (aged 3–18 years) who presented with gastrointestinal symptoms and were treated with or without PPI for at least 1 month were enrolled. Patients were divided into PPI and non-PPI groups. The PPI group was further subdivided by treatment duration and type of PPI used. Stool samples were collected for FC evaluation at baseline and after treatment and clinical data and FC levels were compared between the groups. Results: Fifty-one patients (15 boys, 36 girls) were enrolled in the study. The PPI group included 37 patients, while the non-PPI group included 14 patients. Clinical symptoms were not significantly different. FC levels and laboratory results, including C-reactive protein levels, white blood cell count, and absolute neutrophil count, were not statistically different before versus after PPI treatment. After treatment, FC levels decreased to 8.1 mg/kg (-575.4 to 340.3 mg/kg) in the PPI group and increased to 5.6 mg/kg (-460.0 to 186.9 mg/kg) in the non-PPI group compared to those before treatment (P=0.841). The number of patients with increased FC levels was not significantly different between the 2 groups (48.6% vs. 64.3%, P=0.363), similar to that observed in patients with an FC level > 50 mg/kg (24.3% and 7.1%, P=0.250). PPI therapy type and duration did not affect the FC levels (P=0.811 and P=0.502, respectively). Conclusion: Although we aimed to confirm the evidence of intestinal inflammation due to PPI use in children and adolescents through clinical symptoms and FC measurement, no significant changes were observed. © 2019 by The Korean Pediatric Society.
Files in This Item
Appears in
Collections
ETC > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Chae, Soo Ahn photo

Chae, Soo Ahn
의과대학 (의학부(임상-서울))
Read more

Altmetrics

Total Views & Downloads

BROWSE